The inaugural FierceMedTech Fierce 15—a call for nominations

Send us your nominations for the 2017 FierceMedTech Fierce 15.

Each year, our crop of Fierce 15 honorees includes an increasing number of nontraditional device players. From Glooko and Propeller Health—both digital disease management platforms—to image analysis players Arterys and Zebra Medical, the way we think about medical technology and devices has changed considerably.

So much so that the FDA rolled out a new program this summer aimed at creating a new regulatory pathway to accommodate digital health software that poses a lower risk than traditional medical devices.

“FDA’s traditional approach to medical devices is not well suited to these [digital health products]. We need to make sure our approach to innovative products with continual updates and upgrades is efficient and that it fosters, not impedes, innovation,” said FDA Commissioner Scott Gottlieb at the time.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

In a nod to the rise of new medical technologies, FierceMedicalDevices became FierceMedTech earlier this year. Now, we are selecting our first medtech Fierce 15—and we need your help. We are looking for medtech pioneers at the cutting edge of their field, adapting current technology, or creating entirely new systems to treat disease.

Know a medtech startup transforming the way a disease is diagnosed or treated? Let us know in the nomination form below. Check out last year’s honorees to see the type of companies we're looking for. Nominations close on Oct. 16.

The nominees should meet the following criteria:

  • Companies must be privately held, not publicly traded.
  • Companies should be working on treatments for human diseases.
  • Executives must be available for interviews and agree to keep their status in our selection process confidential until the final list is announced.

 

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.